纳武利尤单抗联合伊匹木单抗治疗无症状脑转移黑色素瘤患者:多中心III期NIBIT-M2试验的7年结局与生活质量
III期NIBIT-M2研究先前报告伊匹木单抗联合纳武利尤单抗治疗无症状脑转移黑色素瘤患者4年总生存率为41%。本次报告7年疗效与健康相关生活质量分析:截至2023年5月1日,中位随访67个月,C组(伊匹木单抗联合纳武利尤单抗)中位OS为29.2个月,7年OS率为42.8%,所有治疗组HRQoL均得以保持。
要点
- C组(伊匹木单抗联合纳武利尤单抗)中位OS为29.2个月,7年OS率为42.8%。
- A组(福莫司汀)中位OS为8.5个月,7年OS率为10.0%;B组(伊匹木单抗联合福莫司汀)中位OS为8.2个月,7年OS率为10.3%。
- 所有治疗组HRQoL均得以保持,C组功能量表评分下降更少。
核心结论
- 在无症状脑转移黑色素瘤患者中,NIBIT-M2研究显示伊匹木单抗联合纳武利尤单抗持续具有疗效,同时保持HRQoL。
研究设计与样本
- III期NIBIT-M2研究,多中心,纳入无症状脑转移黑色素瘤患者,比较A组福莫司汀、B组伊匹木单抗联合福莫司汀、C组伊匹木单抗联合纳武利尤单抗。
- 本次报告7年疗效结局和健康相关生活质量(HRQoL)分析,截至2023年5月1日,中位随访67个月。
主要发现
- 中位OS:A组8.5个月(95%CI:6.6-10.3),B组8.2个月(95%CI:2.1-14.3),C组29.2个月(95%CI:0-69.9)。
- 7年OS率:A组10.0%(95%CI:0-22.5),B组10.3%(95%CI:0-22.6),C组42.8%(95%CI:23.4-62.2)。
- HRQoL在所有治疗组均得以保持;从基线至第12周,多数功能量表保持,C组EORTC QLQ-C30平均评分下降更少,EORTC QLQ-BN20平均评分升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab. METHODS: Here, we report the 7-year efficacy outcomes and the Health-Related Quality of Life (HRQoL) analyses of the NIBIT-M2 study. RESULTS: As of May 1, 2023, at a median follow-up of 67 months (mo), the median OS was 8.5 (95% CI: 6.6-10.3), 8.2 (95% CI: 2.1-14.3) and 29.2 (95% CI: 0-69.9) mo for the fotemustine (F) Arm A, ipilimumab plus fotemustine Arm B, and ipilimumab plus nivolumab Arm C, respectively. The 7-year OS rate was 10.0% (95% CI: 0-22.5) in Arm A, 10.3% (95% CI: 0-22.6) in Arm B, and 42.8% (95% CI: 23.4-62.2) in Arm C. HRQoL was preserved in all treatment arms. Most functional scales evaluated from baseline to W12 were preserved, with a lower mean score decrease for EORTC Quality of Life Questionnaire (QLQ)-C30 and an increase for EORTC QLQ-Brain neoplasm (BN20) in patients receiving ipilimumab plus nivolumab. CONCLUSIONS: With the longest follow-up available to date in melanoma patients with asymptomatic brain metastases, the NIBIT-M2 study continues to show persistent therapeutic efficacy of I ipilimumab plus nivolumab while preserving HRQoL.
引用
- Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, et al. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Eur J Cancer. 2024. PMID: 38271746. doi:10.1016/j.ejca.2024.113531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。